Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma

D. S. Carroll, Richard J. Gralla, N. E. Kemeny

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Twenty-one patients with metastatic colorectal carcinoma were treated with weekly injections of PALA. Rash and diarrhea were the most common and limiting side effects. The incidence of serious toxicity could not be predicted on the basis of liver function tests but was increased in patients with a creatinine level of ≥1.5 mg/100 ml. The neurologic toxicity observed in 21% of the patients was seen in one patient with intracerebral structural lesions and in other patients in whom no such lesions could be found. Similar results were seen in other phase II trials with PALA at MSKCC. It is possible that the structural lesions present in some of the patients facilitated entry of PALA into the brain with subsequent encephalopathy and lowering of the seizure threshold. Although abnormal EEGs were found in all patients who developed neurotoxicity, no EEG abnormality was predictive of subsequent neurologic symptoms. Minor responses were seen in two of 19 adequately treated patients. It should be emphasized that the majority of patients in this study were heavily pretreated, although a minor response of 7+ months was seen in a patient who had undergone three prior chemotherapy trials. With a predicted response rate of ≤15% (P=0.05). We conclude that PALA by this dose and schedule is not an effective single agent in previously treated patients with colorectal carcinoma.

Original languageEnglish (US)
Pages (from-to)349-351
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - 1980
Externally publishedYes

Fingerprint

Aspartic Acid
Colorectal Neoplasms
Electroencephalography
Liver Function Tests
Brain Diseases
Neurologic Manifestations
Exanthema
Nervous System
Diarrhea
Creatinine
Appointments and Schedules
Seizures
Drug Therapy
Injections
Incidence
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma. / Carroll, D. S.; Gralla, Richard J.; Kemeny, N. E.

In: Cancer Treatment Reports, Vol. 64, No. 2-3, 1980, p. 349-351.

Research output: Contribution to journalArticle

@article{6c0d27d685ef4046a75e64f4261058bc,
title = "Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma",
abstract = "Twenty-one patients with metastatic colorectal carcinoma were treated with weekly injections of PALA. Rash and diarrhea were the most common and limiting side effects. The incidence of serious toxicity could not be predicted on the basis of liver function tests but was increased in patients with a creatinine level of ≥1.5 mg/100 ml. The neurologic toxicity observed in 21{\%} of the patients was seen in one patient with intracerebral structural lesions and in other patients in whom no such lesions could be found. Similar results were seen in other phase II trials with PALA at MSKCC. It is possible that the structural lesions present in some of the patients facilitated entry of PALA into the brain with subsequent encephalopathy and lowering of the seizure threshold. Although abnormal EEGs were found in all patients who developed neurotoxicity, no EEG abnormality was predictive of subsequent neurologic symptoms. Minor responses were seen in two of 19 adequately treated patients. It should be emphasized that the majority of patients in this study were heavily pretreated, although a minor response of 7+ months was seen in a patient who had undergone three prior chemotherapy trials. With a predicted response rate of ≤15{\%} (P=0.05). We conclude that PALA by this dose and schedule is not an effective single agent in previously treated patients with colorectal carcinoma.",
author = "Carroll, {D. S.} and Gralla, {Richard J.} and Kemeny, {N. E.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "349--351",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2-3",

}

TY - JOUR

T1 - Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma

AU - Carroll, D. S.

AU - Gralla, Richard J.

AU - Kemeny, N. E.

PY - 1980

Y1 - 1980

N2 - Twenty-one patients with metastatic colorectal carcinoma were treated with weekly injections of PALA. Rash and diarrhea were the most common and limiting side effects. The incidence of serious toxicity could not be predicted on the basis of liver function tests but was increased in patients with a creatinine level of ≥1.5 mg/100 ml. The neurologic toxicity observed in 21% of the patients was seen in one patient with intracerebral structural lesions and in other patients in whom no such lesions could be found. Similar results were seen in other phase II trials with PALA at MSKCC. It is possible that the structural lesions present in some of the patients facilitated entry of PALA into the brain with subsequent encephalopathy and lowering of the seizure threshold. Although abnormal EEGs were found in all patients who developed neurotoxicity, no EEG abnormality was predictive of subsequent neurologic symptoms. Minor responses were seen in two of 19 adequately treated patients. It should be emphasized that the majority of patients in this study were heavily pretreated, although a minor response of 7+ months was seen in a patient who had undergone three prior chemotherapy trials. With a predicted response rate of ≤15% (P=0.05). We conclude that PALA by this dose and schedule is not an effective single agent in previously treated patients with colorectal carcinoma.

AB - Twenty-one patients with metastatic colorectal carcinoma were treated with weekly injections of PALA. Rash and diarrhea were the most common and limiting side effects. The incidence of serious toxicity could not be predicted on the basis of liver function tests but was increased in patients with a creatinine level of ≥1.5 mg/100 ml. The neurologic toxicity observed in 21% of the patients was seen in one patient with intracerebral structural lesions and in other patients in whom no such lesions could be found. Similar results were seen in other phase II trials with PALA at MSKCC. It is possible that the structural lesions present in some of the patients facilitated entry of PALA into the brain with subsequent encephalopathy and lowering of the seizure threshold. Although abnormal EEGs were found in all patients who developed neurotoxicity, no EEG abnormality was predictive of subsequent neurologic symptoms. Minor responses were seen in two of 19 adequately treated patients. It should be emphasized that the majority of patients in this study were heavily pretreated, although a minor response of 7+ months was seen in a patient who had undergone three prior chemotherapy trials. With a predicted response rate of ≤15% (P=0.05). We conclude that PALA by this dose and schedule is not an effective single agent in previously treated patients with colorectal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0019154652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019154652&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 349

EP - 351

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2-3

ER -